Used in the treatment of epithelioid sarcoma, a rare type of soft tissue cancer, particularly in patients who are not eligible for complete surgical resection. It is also approved for adult patients with metastatic or locally advanced epithelioid sarcoma. Additionally, it is being investigated in clinical trials for the treatment of other cancers, including follicular lymphoma and diffuse large B-cell lymphoma, especially in cases involving EZH2 gene mutations. As a selective inhibitor of EZH2 (enhancer of zeste homolog 2), it works by modulating gene expression involved in cell proliferation, leading to cancer cell death. Its targeted mechanism makes it valuable in precision oncology, offering a therapeutic option for tumors driven by epigenetic dysregulation.